Differences in health care utilization at the end of life among patients with chronic obstructive pulmonary disease and patients with lung cancer

Archives of Internal Medicine

Volumn 166, Issue 3, 2006, Pages 326-331

  Au, David H ^a,b,c   Udris, Edmunds M ^a   Fihn, Stephan D ^a,b   McDonell, Mary B ^a   Curtis, J Randall ^b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Northwest Health Services Research and Development Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; OPIATE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LUNG CANCER; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL;

AGED; ANALGESICS, OPIOID; BENZODIAZEPINES; COHORT STUDIES; DRUG UTILIZATION; FEMALE; HEALTH CARE COSTS; HOSPITAL MORTALITY; HOSPITALIZATION; HOSPITALS, VETERANS; HUMANS; INTENSIVE CARE UNITS; LUNG NEOPLASMS; MALE; OUTPATIENT CLINICS, HOSPITAL; PALLIATIVE CARE; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 32644446415     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.166.3.326     Document Type: Article

References (24)

1. National Heart, Blood, and Lung Institute. Data Fact Sheet: Chronic Obstructive Pulmonary Disease. Bethesda, Md: National Heart, Blood, and Lung Institute; 2003. NIH publication 30-5229.
2. National Heart, Blood, and Lung Institute/World Health Organization. Global Initiative for Chronic Obstructive Pulmonary Disease: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: NHLBI/WHO Workshop Report. Updated 2003. Available at: http://www.goldcopd.com. Accessed May 1, 2005.
3. American Thoracic Society. Standards for the Diagnosis and Management of Patients With COPD. Updated 2004. Available at: http://www.thoracic.org/copd/. Accessed May 1, 2005.
4. Claessens MT, Lynn J, Zhong Z, et al. Dying with lung cancer or chronic obstructive pulmonary disease: insights from SUPPORT: Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. J Am Geriatr Soc. 2000;48:S146-S153.
5. Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? a comparison of palliative care and quality of life in COPD and lung cancer. Thorax. 2000;55:1000-1006.
6. Wennberg JE. Practice variation: implications for our health care system. Manag Care. 2004;13:3-7.
7. Wennberg JE. Practice variations and health care reform: connecting the dots. Health Aff (Millwood). 2004(suppl Web exclusive):VAR140-VAR144.
8. Fihn SD, McDonell MB, Diehr P, et al. Effects of sustained audit/feedback on selfreported health status of primary care patients. Am J Med. 2004;116:241-248.
9. Cowper DC, Kubal JD, Maynard C, Hynes DM. A primer and comparative review of major US mortality databases. Ann Epidemiol. 2002;12:462-468.
10. Fleming C, Fisher ES, Chang CH, Bubolz TA, Malenka DJ. Studying outcomes and hospital utilization in the elderly. Med Care. 1992;30:377-391.
11. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
12. Phibbs CS, Luft HS. Correlation of travel time on roads versus straight line distance. Med Care Res Rev. 1995;52:532-542.
13. Wennberg JE, Fisher ES, Stukel TA, Skinner JS, Sharp SM, Bronner KK. Use of hospitals, physician visits, and hospice care during last six months of life among cohorts loyal to highly respected hospitals in the United States. BMJ. 2004;328:607.
14. Fox E, Landrum-McNiff K, Zhong Z, Dawson NV, Wu AW, Lynn J; SUPPORT Investigators. Evaluation of prognostic criteria for determining hospice eligibility in patients with advanced lung, heart, or liver disease. JAMA. 1999;282:1638-1645.
15. Herbst LH. Prognosis in advanced pulmonary disease. J Palliat Care. 1996;12:54-56.
16. Manaker S, Tino G. Natural history and prognosis of advanced lung disease. Clin Chest Med. 1997;18:435-455.
17. Roberts RR, Frutos PW, Ciavarella GG, et al. Distribution of variable vs fixed costs of hospital care. JAMA. 1999;281:644-649.
18. Teno J, Lynn J, Connors AF Jr, et al. The illusion of end-of-life resource savings with advance directives: SUPPORT Investigators: Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. J Am Geriatr Soc. 1997;45:513-518.
19. Luce JM, Rubenfeld GD. Can health care costs be reduced by limiting intensive care at the end of life? Am J Respir Crit Care Med. 2002;165:750-754.
20. Heffner JE, Fahy B, Hilling L, Barbieri C. Attitudes regarding advance directives among patients in pulmonary rehabilitation. Am J Respir Crit Care Med. 1996;154:1735-1740.
21. Curtis JR, Wenrich MD, Carline JD, Shannon SE, Ambrozy DM, Ramsey PG. Patients' perspectives on physician skill in end-of-life care: differences between patients with COPD, cancer, and AIDS. Chest. 2002;122:356-362.
22. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343:1902-1909.
23. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297-1303.
24. Hansen-Flaschen J. Chronic obstructive pulmonary disease: the last year of life. Respir Care. 2004;49:90-98.